

**HEARING SCREENING TRACKING**

Initial IFSP      Annual IFSP

Child's Name (*Last, First, M.I.*): \_\_\_\_\_ Date of Birth: \_\_\_\_\_Mother's Maiden Name: \_\_\_\_\_ Birth Order (*Multiples*):    A    B    C    D

Date: \_\_\_\_\_ Birthing Hospital: \_\_\_\_\_

**1. Review of Medical History/Records**

Previously Diagnosed Hearing Loss?    Yes    No

<b>Newborn Hearing Screening</b>							
In-Patient Results:	OAE	Pass	Refer		ABR	Pass	Refer
	Right				Right		
	Left				Left		
<b>Outpatient Screen (<i>follow-up from Newborn Screen</i>)</b>							
Out-Patient Results:	OAE	Pass	Refer		ABR	Pass	Refer
	Right				Right		
	Left				Left		

Date: \_\_\_\_\_ Where was screening completed? \_\_\_\_\_

**Hearing Evaluation ABR**

Where was test completed? \_\_\_\_\_ Date: \_\_\_\_\_

Results: \_\_\_\_\_ Recommendations: \_\_\_\_\_

**Hearing Evaluation Behavior Testing (*audiogram*)**

Where was test completed? \_\_\_\_\_ Date: \_\_\_\_\_

Results: \_\_\_\_\_ Recommendations: \_\_\_\_\_

**2. Indicators for Children Who are at Risk for Late Onset or Progressive Hearing Losses****(Check risk factors that are present)**

Parental/ caregiver concern regarding hearing, speech, language, and or developmental delay.

Family history of permanent childhood hearing loss.

Postnatal infections associated with sensorineural hearing loss including bacterial meningitis.

Head trauma.

Recurrent/ persistent otitis media with effusion for at least 3 months.

Stigmata/ other findings associated with a syndrome known to include sensorineural/ conductive hearing loss/Eustachian tube dysfunction.

Syndromes associated with progressive hearing loss such as neurofibromatosis, osteopetrosis and Usher's syndrome.

Neonatal indicators-specifically hyperbilirubinemia at a serum level requiring exchange transfusion, persistent pulmonary hypertension of the newborn associated with mechanical ventilation, and conditions requiring the use of extracorporeal membrane oxygenation (ECHMO).

Neurodegenerative disorders, such as Hunter syndrome, or sensory motor neuropathies, such as Friedreich's ataxia and Charcot-Marie-Tooth syndrome.

Chemo-therapy.

**Guideline For Follow-up Hearing Screening:**

- If a child passed a newborn hearing screening within the last 6 months and presents with no risk factors for late-onset or progressive hearing loss, then the child does not need further objective screening for one year.
- If a child does not pass the screening the child should get a follow-up hearing screening within 2-4 weeks. If the child does not pass the follow-up screening, they should receive a medical evaluation of the middle ear and evaluation by a pediatric audiologist to rule out hearing loss.

**Results of Hearing Screening:**

Date: \_\_\_\_\_ Screener: \_\_\_\_\_

Visual Inspection		Right	Pass	Refer	
		Left	Pass	Refer	
OAE	Pure Tone	Right	Pass	Refer	Could not test
		Left	Pass	Refer	Could not test
Tympanometry		Right	Pass	Refer	Could not test
		Left	Pass	Refer	Could not test

**Rescreen:**

Date: \_\_\_\_\_ Screener: \_\_\_\_\_

Visual Inspection		Right	Pass	Refer	
		Left	Pass	Refer	
OAE	Pure Tone	Right	Pass	Refer	Could not test
		Left	Pass	Refer	Could not test
Tympanometry		Right	Pass	Refer	Could not test
		Left	Pass	Refer	Could not test

Recommendations: \_\_\_\_\_

Referred to: \_\_\_\_\_ Date: \_\_\_\_\_

Service Coordinator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_